Click here to access the guidelines/NICE algorithm				
N&WICS - TA407 - Secukinumal	o - Active ankylosing spondylitis a alpha in	fter treatment with non-steroidal an hibitors	ti-inflammatory drugs or TNF	F-
parent/legal guardian/carer) has give CSU for processing this funding req If there is more than one NICE-appr about the advantages and disadvan- patient is likely to adhere to treatment	data on this form, please confirm that en appropriate explicit consent for ser uest and validating subsequent invoice oved treatment available, a discussion ages of the treatments available. Thi	the patient (or in the case of a minor of the case. Consent given: In between the responsible clinician and is has taken into consideration theraped nsive, will be chosen (taking into accounts).	the patient has taken place utic need and whether or not the	e
Patient NHS No:	Trust:	Practice Name:		
Patient Hospital No:	Consultant Making Request:	Practice Postcode:		
Patient's Initials and DoB:		Practice Code:		
Notification Email Address:	(@NHS.net accou	nt ONLY) Contact name & number:		
Start date of requested treatment:	Provider: Private Ne Supplier: Homecare	Hospital Sub-Type:	J/A ✓	
For support regarding IFRs, please		require an individual funding request (ntariff@nhs.net	IFR).	
Please indicate whether patien	nt meets the following NICE criter	ia:	Please tick	
ankylosing spondylitis in adults w steroidal anti-inflammatory drugs	I, within its marketing authorisation, a hose disease has responded inadeque or TNF-alpha inhibitors). The drug is ed in the patient access scheme.	uately to conventional therapy (non-	☐Yes ☐No	
Assess the response to secukinumab after 16 weeks of treatment and only continue if there is clear evidence of response, defined as:				
• a reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score to 50% of the pretreatment value or by 2 or more units and				
a reduction in the spinal pain visual analogue scale (VAS) by 2 cm or more.				
3. When using BASDAI and spinal pain VAS scores, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect the responses to the questionnaires, and make any adjustments they consider appropriate.				
	ent should normally be started with the and any additional administration co			
1	•	ective treatment for this individual CE may be lower in cost, including the	□Yes □No	
		en tried by the patient, please confirm ents' medical record for the purpose of		

I confirm that the patient meets the criteria for treatment

Name of person completing:	Contact Details:			
Designation of person completing:	Date:			
Trust Authorising Pharmacist				
Name: Date:				